Pulmonary Embolectomy System Market 2026-2032: The USD 1.86 Billion Interventional Revolution Redefining Acute Pulmonary Embolism Care
Global Leading Market Research Publisher QYResearch announces the release of its latest report ”Pulmonary Embolectomy System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pulmonary Embolectomy System market, including market size, share, demand, industry development status, and forecasts for the next few years.
For interventional cardiologists who recognize that acute pulmonary embolism kills approximately 60,000-100,000 Americans annually—making it a leading cause of cardiovascular death—and for hospital administrators evaluating the clinical and economic case for building catheter-directed thromboembolectomy programs, the treatment paradigm has shifted decisively. Systemic anticoagulation alone fails to actively remove thrombus burden in intermediate-risk patients who continue deteriorating. Surgical embolectomy, while effective, requires sternotomy and cardiopulmonary bypass, limiting its applicability to the most critically ill. Catheter-based pulmonary embolectomy systems occupy the expanding therapeutic window between these extremes. The global market for Pulmonary Embolectomy System was estimated to be worth USD 1,110 million in 2025 and is projected to reach USD 1,860 million by 2032, growing at a CAGR of 7.6% from 2026 to 2032 .
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6695436/pulmonary-embolectomy-system
Market Size and Device Economics: 113,300 Units Deployed at USD 9,800 Average Selling Price
In 2025, the average selling price is approximately USD 9,800 per unit, global sales volume is about 113,300 units, and gross margins generally range from 50% to 70%, driven by catheter material costs, device design complexity, regulatory approval barriers, and physician training requirements . These unit economics reflect a market where procedural volume is growing as clinical evidence accumulates, guideline recommendations broaden, and hospital catheterization laboratories develop the specialized expertise required for pulmonary artery interventions. The gross margin structure—50% to 70%—is characteristic of interventional cardiology devices where proprietary catheter engineering, polymer science, and regulatory moats combine to create durable pricing power.
Product Definition: Minimally Invasive Thrombus Extraction from the Pulmonary Arteries
Pulmonary embolectomy systems are specialized medical devices designed for the minimally invasive removal of thromboemboli from the pulmonary arteries to restore hemodynamic stability in patients with acute pulmonary embolism. These systems typically comprise aspiration catheters, mechanical thrombectomy devices, guidewires, and negative pressure aspiration pumps. Unlike traditional surgical embolectomy, catheter-based techniques achieve thrombus removal through percutaneous access, offering reduced procedural trauma, shorter hospital stays, and improved clinical outcomes for intermediate- and high-risk patients. Key technologies include large-bore aspiration catheters, mechanical fragmentation devices, and rheolytic thrombectomy systems .
The value chain is structured across three tiers. Upstream includes catheter material suppliers (medical-grade polymers, braiding wires), guidewire component manufacturers, aspiration pump and console producers, and packaging/sterilization service providers. Midstream involves device assembly, quality control, regulatory certification (FDA, CE, NMPA), and distribution. Downstream demand spans interventional cardiology departments, vascular surgery departments, interventional radiology departments, and intensive care units in hospitals .
Market Dynamics: Disease Burden, Guideline Expansion, and Technological Innovation
The pulmonary embolectomy system market is experiencing robust growth driven by the increasing global incidence of pulmonary embolism and the paradigm shift toward minimally invasive catheter-based interventions over traditional surgical embolectomy. According to the CDC, approximately 900,000 people in the United States are affected by deep vein thrombosis and pulmonary embolism annually, with about 60,000-100,000 deaths. This high disease burden, coupled with the availability of effective mechanical thrombectomy devices, has created substantial demand for pulmonary embolectomy systems .
A critical structural catalyst is the expansion of treatment guidelines that now recommend catheter-directed therapies for intermediate-risk pulmonary embolism patients. Previously, systemic anticoagulation was the standard of care for non-massive PE, but growing evidence supports the use of mechanical thrombectomy to reduce right ventricular strain, improve long-term functional outcomes, and prevent chronic thromboembolic pulmonary hypertension. This guideline expansion has significantly broadened the addressable patient population for pulmonary embolectomy systems. The American Heart Association, European Society of Cardiology, and other major guideline bodies have progressively incorporated catheter-directed therapy recommendations, creating the evidence-based framework that hospital pharmacy and therapeutics committees require for device formulary approval.
The market is also witnessing significant technological innovation in next-generation thrombectomy devices. Key trends include the development of dual-action devices combining aspiration and mechanical fragmentation, enhanced navigability through complex pulmonary arterial anatomy, and real-time pressure monitoring for safer aspiration . These innovations are improving procedural efficiency, reducing blood loss, and enabling interventionalists to treat more extensive thrombus burden than was feasible with first-generation aspiration-only catheters. The most advanced platforms now integrate computer-assisted vacuum control that modulates aspiration pressure based on real-time catheter tip position, reducing the risk of vascular injury during thrombus extraction.
Technology Segmentation: Catheter Bore Size Defines Clinical Applicability
The Pulmonary Embolectomy System market is segmented by type into Large-Bore Aspiration Catheter (>12F), Medium-Bore Aspiration Catheter (8-12F), and Small-Bore Aspiration Catheter (<8F). Large-bore aspiration catheters represent the dominant product segment, driven by their ability to rapidly extract substantial thrombus volume from the main and proximal lobar pulmonary arteries where the most clinically significant obstructions occur. The trade-off—larger access site requirements and potentially greater blood loss during aspiration—is clinically acceptable in the intermediate-risk and high-risk patients for whom these devices are indicated.
Medium-bore catheters are gaining adoption for segmental and subsegmental pulmonary artery interventions where smaller vessel diameter precludes large-bore access, and for patients in whom femoral or internal jugular venous access sites cannot accommodate larger introducer sheaths. Small-bore catheters serve specialized applications including distal thrombus aspiration and pediatric pulmonary embolism cases. The technology diversity reflects the anatomical complexity of the pulmonary arterial tree, which branches through multiple generations of progressively smaller vessels, each requiring appropriately sized intervention tools.
Application Landscape: Academic Medical Centers Lead, Community Hospitals Accelerate
The application segmentation spans Tertiary/Academic Medical Center, Regional/Community Hospital, and Specialized Cardiovascular Center. Academic medical centers represent the dominant procedural volume, driven by the concentration of interventional cardiology and interventional radiology expertise, 24/7 catheterization laboratory availability, and the clinical research infrastructure that generates the evidence supporting guideline expansion. Specialized cardiovascular centers are capturing a growing share as high-volume interventional practices develop dedicated pulmonary embolism response teams (PERTs) that coordinate rapid multi-specialty assessment and treatment.
Regional and community hospitals represent the fastest-growing application segment, as catheter-directed thromboembolectomy technology diffuses beyond academic centers into the community settings where the majority of acute pulmonary embolism patients initially present. This diffusion requires both device simplification that enables safe use by interventionalists without dedicated pulmonary embolism specialization, and the development of telemedicine-enabled PERT models that connect community hospital emergency departments with academic center specialists for real-time procedural guidance.
Competitive Landscape: Interventional Cardiology Leaders and Specialized Thrombectomy Innovators
Key market participants profiled in this report include Inari Medical, Inc., Penumbra, Inc., Boston Scientific Corporation, Medtronic plc, Teleflex Incorporated, Johnson & Johnson (Ethicon), Terumo Corporation, Kaneka Corporation, MicroPort Scientific Corporation, Lepu Medical Technology Co., Ltd., Avinger, Inc., Argon Medical Devices, and Control Medical Technology .
The competitive landscape reflects the convergence of established interventional cardiology device manufacturers and specialized thrombectomy innovators. Inari Medical has established a commanding market position through its dedicated FlowTriever platform—the first FDA-cleared device specifically indicated for pulmonary embolectomy—creating a first-mover advantage in both clinical evidence generation and physician training infrastructure. Penumbra’s Indigo aspiration system leverages the company’s neurovascular thrombectomy expertise in the pulmonary circulation. Boston Scientific and Medtronic bring extensive interventional cardiology commercial infrastructure and established hospital relationships. Chinese manufacturers including MicroPort and Lepu Medical are capturing domestic market share through competitive pricing and government hospital procurement relationships under China’s volume-based procurement policies.
Exclusive Observation: The PERT-Enabled Versus Non-PERT Hospital Market Bifurcation
Drawing on extensive medical device market analysis, a critical segmentation deserves strategic attention: the distinction between pulmonary embolectomy system adoption in hospitals with established Pulmonary Embolism Response Teams versus hospitals without dedicated PERT infrastructure. PERT-enabled hospitals—typically academic medical centers and large regional referral centers—maintain 24/7 multi-specialty teams comprising interventional cardiology, interventional radiology, cardiac surgery, and critical care that can rapidly assess pulmonary embolism patients and mobilize catheter-directed therapy within hours of presentation. These hospitals generate substantially higher annual procedural volumes and are more likely to adopt premium-priced next-generation devices with advanced features including real-time pressure monitoring and dual-action thrombectomy.
Non-PERT hospitals—typically community hospitals and smaller regional facilities—manage pulmonary embolism patients through ad hoc consultations without standardized protocols, resulting in lower and less predictable device utilization. This segment represents both the greatest growth opportunity and the greatest commercial challenge: capturing these accounts requires not only device supply but also clinical education, protocol development support, and telemedicine infrastructure that connects community interventionalists with PERT expertise. Manufacturers that invest in comprehensive PERT development programs—rather than merely selling devices—will capture disproportionate share in this expanding community hospital segment.
Industry Challenge: Reimbursement, Training, and the Evidence Imperative
The defining challenge confronting the pulmonary embolectomy system market is the transition from procedure codes that inadequately capture the complexity of catheter-directed pulmonary thromboembolectomy to appropriate reimbursement that supports hospital investment in device inventory and PERT infrastructure. Physician training represents a parallel constraint: pulmonary artery intervention requires skills distinct from coronary or peripheral vascular procedures, and the relatively small number of high-volume operators limits procedural diffusion.
The 2025 U.S. tariff adjustments on imported medical device components—including medical-grade polymers, braiding wires, and catheter subassemblies—have introduced supply chain recalibration pressures that particularly affect manufacturers dependent on global sourcing strategies for critical raw materials . Manufacturers with diversified, multi-regional supply chains are positioned to navigate this trade environment more effectively.
Strategic Outlook Through 2032
The pulmonary embolectomy system market’s trajectory toward USD 1,860 million by 2032 is underpinned by structural forces of compounding intensity: the high and potentially underdiagnosed disease burden of acute pulmonary embolism, the progressive expansion of treatment guidelines that now recommend catheter-directed therapy for intermediate-risk patients, and the technological innovation delivering next-generation dual-action thrombectomy devices that improve procedural efficiency and expand the treatable patient population. For interventional cardiologists, hospital administrators building PERT programs, and medical device investors, the pulmonary embolectomy system market represents a strategically essential growth vertical at the intersection of interventional cardiology innovation, guideline-driven practice change, and unmet clinical need in one of cardiovascular medicine’s most lethal acute conditions.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
